87E Stock Chart & Stats
€90.50
-€2.00(-2.16%)
At close: 4:00 PM EDT
€90.50
-€2.00(-2.16%)
Day’s Range― - ―
52-Week Range€19.90 - €99.50
Previous CloseN/A
Volume67.00
Average Volume (3M)13.00
Market Cap
€5.53B
Enterprise Value€4.58K
Total Cash (Recent Filing)€886.81M
Total Debt (Recent Filing)€1.29M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Nov 05, 2026EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding55,934,380
10 Day Avg. Volume7
30 Day Avg. Volume13
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.16
Price to Sales (P/S)764.98
P/FCF Ratio-12.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€121.48Price Target Upside34.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.3
Revenue Forecast (FY)€1.54M
Bulls Say, Bears Say
Bulls Say
Phase 3 Clinical ProgressThe interim response rate supports clinical proof-of-concept for claseprubart and may strengthen its prospects in chronic inflammatory demyelinating polyneuropathy, creating a potentially meaningful commercial opportunity if later-stage results remain supportive.
Strong Cash PositionSubstantial liquidity and an extended operating runway can fund clinical development without immediate dependence on capital markets, allowing Dianthus to pursue multiple milestones and preserve strategic flexibility through later development stages.
Pipeline DiversificationA second autoimmune program across several rheumatology indications reduces reliance on a single neuromuscular asset and creates additional opportunities for portfolio growth, while multiple clinical milestones could broaden the company’s long-term competitive position.
Bears Say
Rising Cash BurnIncreasing operating cash outflows show that development activity is consuming capital at a growing rate. Even with substantial liquidity, sustained burn raises execution and financing risks if programs require longer or more costly trials than planned.
Persistent Operating LossesThe company lacks operating scale and remains dependent on future clinical success rather than recurring commercial revenue. Persistent losses and declining or volatile revenue limit internal funding capacity and make profitability dependent on successful product launches.
No Commercial Product RevenueAs a clinical-stage biotechnology company, Dianthus has not established a commercial revenue base to offset research and development costs. Its fundamental outlook therefore remains highly dependent on trial outcomes, regulatory progress and eventual commercialization.
Dianthus Therapeutics News
87E FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was €19.90 and its highest was €99.50 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is €5.53B.
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 76 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on Aug 04, 2026. The company reported -€0.78 earnings per share for the quarter, missing the consensus estimate of -€0.733 by -€0.047.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -0.86.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 55,934,380 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -€0.78 in its last earnings report, missing expectations of -€0.733. Following the earnings report the stock price went up 3.261%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Currently, no hedge funds are holding shares in DE:87E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dianthus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€121.48 (34.23% Upside)
€121.48 (34.23% Upside)
Blogger Sentiment
Bullish
DE:87E Sentiment 67%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth €11.8M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
376.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
272.08%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
87E Stock 12 Month Forecast
Average Price Target
€121.48
▲(34.23% Upside)
Technical Analysis
Ardelyx
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Amylyx Pharmaceuticals Inc
―
Biohaven Ltd.
―